Merus N.V. (MRUS)
NASDAQ: MRUS · Real-Time Price · USD
41.85
-0.24 (-0.57%)
Dec 20, 2024, 4:00 PM EST - Market closed
Merus Revenue
Merus had revenue of $11.77M in the quarter ending September 30, 2024, with 6.70% growth. This brings the company's revenue in the last twelve months to $35.93M, down -21.33% year-over-year. In the year 2023, Merus had annual revenue of $43.95M with 5.68% growth.
Revenue (ttm)
$35.93M
Revenue Growth
-21.33%
P/S Ratio
71.65
Revenue / Employee
$156,908
Employees
229
Market Cap
2.87B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 43.95M | 2.36M | 5.68% |
| Dec 31, 2022 | 41.59M | -7.52M | -15.32% |
| Dec 31, 2021 | 49.11M | 19.16M | 64.00% |
| Dec 31, 2020 | 29.94M | -1.19M | -3.82% |
| Dec 31, 2019 | 31.13M | -7.25M | -18.88% |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
| Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Patterson Companies | 6.55B |
| QuidelOrtho | 2.82B |
| Amedisys | 2.32B |
| ACADIA Pharmaceuticals | 929.24M |
| Warby Parker | 742.53M |
| iRhythm Technologies | 560.03M |
| Amicus Therapeutics | 493.67M |
| Zai Lab | 355.75M |
MRUS News
- 5 days ago - Merus announces First Patient Dosed in Phase 2 Trial of Petosemtamab in 3L+ mCRC - GlobeNewsWire
- 15 days ago - Merus' Petosemtamab Monotherapy Interim Data Continues to Demonstrate Clinically Meaningful Activity in 2L+ r/m HNSCC - GlobeNewsWire
- 16 days ago - Merus Scores Its First FDA Approval For Lung Cancer Drug - Benzinga
- 17 days ago - Merus Announces FDA Approval of BIZENGRI® (zenocutuzumab-zbco) for NRG1+ Pancreatic Adenocarcinoma and NRG1+ Non–Small Cell Lung Cancer (NSCLC) Based on Safety and Efficacy Data From the eNRGy Study - GlobeNewsWire
- 17 days ago - US FDA approves Merus' therapy to treat lung, pancreatic cancers - Reuters
- 19 days ago - Merus and Partner Therapeutics Announce License Agreement for the U.S. Commercialization of Zenocutuzumab in NRG1 Fusion-Positive Cancer - GlobeNewsWire
- 20 days ago - Merus Announces Publication of an Abstract on Petosemtamab as 2L+ treatment of r/m HNSCC at the ESMO Asia Congress 2024 - GlobeNewsWire
- 6 weeks ago - Merus to Present at Upcoming Investor Conferences - GlobeNewsWire